Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$156.17
pos +1.50
+0.99%
Today's Range: 153.76 - 156.67 | AMGN Avg Daily Volume: 3,441,300
Last Update: 01/29/15 - 3:30 PM EST
Volume: 2,654,266
YTD Performance: -2.92%
Open: $154.89
Previous Close: $154.64
52 Week Range: $108.20 - $173.14
Oustanding Shares: 760,670,000
Market Cap: 120,862,856,300
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 2 2
Hold 8 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.11 2.11 2.11
Latest Dividend: 0.79
Latest Dividend Yield: 1.99%
Dividend Ex-Date: 02/10/15
Price Earnings Ratio: 18.26
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
18.26 25.00 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.62% 28.12% 126.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $2.05 $2.38 $9.29 $10.57
Number of Analysts 7 6 9 9
High Estimate $2.17 $2.45 $9.38 $11.70
Low Estimate $1.95 $2.29 $9.20 $10.15
Prior Year $1.86 $2.37 $8.68 $9.29
Growth Rate (Year over Year) 10.29% 0.56% 7.01% 13.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?
By

Kate Stalter

 | Jan 6, 2015 | 12:00 PM EST

They are prone to being whipsawed by news.

updateAmgen rated new Equal-weight at Barclays

Jan 6, 2015 | 7:48 AM EST

AMGN was initiated with an Equal-weight rating, Barclays said. Company will struggle to sustain the momentum from 2014. $180 price target. 

bearishAmgen downgraded at Morgan Stanley

Jan 5, 2015 | 6:34 AM EST

AMGN was downgraded to Equal-weight from Overweight, Morgan Stanley said. $177 price target. Valuation call, as the company lacks near-term catalysts.  

By

Timothy Collins

 | Dec 22, 2014 | 3:26 PM EST

Every trade should have a thesis and a catalyst.

By

Timothy Collins

 | Dec 16, 2014 | 3:48 PM EST

Why I'm looking at the iShares Biotech ETF and Amgen.

By

Jim Cramer

 | Dec 8, 2014 | 5:08 AM EST

A litany of reasons why you should calm your nerves.

By

Jim Cramer

 | Dec 2, 2014 | 11:38 AM EST

In this era of turmoil, investors can take comfort in this sector.

bullishAmgen upgraded at Nomura

Oct 29, 2014 | 6:28 AM EDT

AMGN was upgraded from Neutral to Buy, Nomura said. $193 price target. Company has cut costs and can expand the operating margin by 15 points by 2018.

By

Doug Kass

 | Oct 27, 2014 | 7:51 AM EDT
Where it began.
Remember IF that last low in LNKD is good, we should hold on a pullback to it....Note we a...
Auditor of REITs in American Realty Capital Resigned The Grant Thornton accounting firm re...
Market slightly down as oil continues to fail to find a floor and now under $44 a share. ...
IBM failed on Monday after bumping up against a declining 50 day moving average. The...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.